Table 5.
Sufentanil plasma concentrations, by subgroup
| 1 h |
12 h |
|||
|---|---|---|---|---|
| Patients, No. | Mean (SD) pg/mL | Patients, No. | Mean (SD) pg/mL | |
| Age, y | ||||
| <65 | 110 | 35.1 (20.5) | 110 | 27.1 (24.6) |
| ≥65 | 24 | 47.1 (28.4) | 20 | 48.3 (40.6) |
| Sex | ||||
| Male | 62 | 37.0 (19.4) | 65 | 29.8 (26.5) |
| Female | 72 | 37.4 (25.0) | 65 | 30.9 (30.5) |
| BMI, kg/m2 | ||||
| <30 | 75 | 36.4 (23.3) | 73 | 29.8 (30.1) |
| ≥30 | 59 | 38.3 (21.6) | 57 | 31.1 (26.5) |
| Hepatic function* | ||||
| Normal | 98 | 37.7 (22.9) | 96 | 29.4 (28.4) |
| Impaired, by severity | ||||
| Mild | 33 | 35.9 (22.3) | 32 | 33.3 (30.5) |
| Moderate | 2 | 33.6 (15.5) | 2 | 26.4 (4.4) |
| Severe | 1 | 42.4 (NA) | 0 | NA |
| Renal function† | ||||
| Normal | 124 | 37.0 (22.6) | 120 | 29.4 (28.5) |
| Impaired, by severity | ||||
| Mild | 5 | 42.1 (11.3) | 5 | 46.9 (36.2) |
| Moderate | 5 | 36.5 (30.1) | 5 | 35.9 (16.1) |
| Total | 134 | 37.2 (22.5) | 130 | 30.4 (28.5) |
BMI = body mass index.
*
The mean number of study drug doses used was similar for patients with normal hepatic function (3.3, SD = 1.9) and those with mild (3.6, SD = 1.9), moderate (3.0, SD = 0.0), or severe (3.0, SD = not applicable) hepatic impairment.
†
The mean number of study drug doses used was similar for patients with normal renal function (3.3, SD = 1.8) and those with mild (4.2, SD = 2.3) or moderate (3.4, SD = 1.1) renal impairment.